Indication
von Willebrand disease
5 clinical trials
7 products
Product
wilateClinical trial
Clinical Study to Investigate the Efficacy, Pharmacokinetics, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease Patients Under the Age of 6 YearsStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Evaluation of the Pharmacokinetic Profile, Clinical Efficacy and Safety of the Von Willebrand Factor Contained in FANHDI® (Double-inactivated Human Anti-hemophilic Factor) in Pediatric Subjects With Severe Von Willebrand DiseaseStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Observational Registry of Patients With Von WilLEbrand Disease Treated With Voncento®Status: Completed, Estimated PCD: 2023-12-31
Product
Voncento®Clinical trial
A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand DiseaseStatus: Recruiting, Estimated PCD: 2025-01-01
Product
Antihemophilic FactorProduct
von Willebrand factorClinical trial
Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia AStatus: Recruiting, Estimated PCD: 2025-11-01
Product
Emicizumab